CN Bio, a number one Organ-on-a-chip Firm (OOC) that designs and manufactures single-and multi-organ microphysiological programs (MPS), at the moment introduced the appointment of Dr Paul Brooks, previously the Firm’s Chief Enterprise Officer, to the place of CEO with rapid impact. Former CEO, Dr David Hughes, will proceed to work with the corporate in a consultative position inside the Firm’s Scientific Advisory Board.
Dr Paul Brooks. Picture Credit score: CN Bio
Paul’s appointment signifies the subsequent stage of CN Bio’s business improvement. He will probably be centered on driving the Firm’s international growth plans, to succeed in new clients and create worth for shareholders. Having joined the Firm as Chief Enterprise Officer in Might 2022, Paul was liable for shaping CN Bio’s business enterprise, growth technique and overseeing accelerated progress of the Firm’s PhysioMimix™ OOC vary of MPS, consumables, kits and companies. On this time, CN Bio additionally doubled the laboratory house devoted to its contract analysis companies, in response to rising demand for the Firm’s OOC experience by pharma and biotech corporations.
With over 25 years’ expertise within the Life Science sector, Paul is an skilled C-suite degree government; previous to becoming a member of CN Bio he was Head of Enterprise Operations & Managing Director for PerkinElmer’s Horizon Discovery, the place he led the strategic and operational transformation of its enterprise items. All through his profession, Paul has supported profitable progress throughout a broad vary of corporations, together with Head of Discovery Analysis Companies & Normal Supervisor at Sigma-Aldrich (now Merck KGaA), and as Chief Industrial Officer & Government Director and Board member at Oxford Genetics, driving its transformation from start-up firm to commercialization. Paul accomplished his PhD in Molecular Biology from the College of Manchester Institute of Science and Know-how and holds an MBA from Nottingham Enterprise College.
As a part of the Scientific Advisory Board, CN Bio will proceed to learn from Dr David Hughes’ area experience and in depth technical bioengineering background. On this consultative position, Dr Hughes will stay concerned sooner or later improvement of CN Bio’s product and repair portfolio.
I wish to thank David for his management of CN Bio via a transformational time, and I stay up for working with him as we start to completely exploit our unbelievable innovation engine. I’m honored to be appointed CEO at a pivotal time within the Firm’s, and the trade’s, evolution, as the worth of well-characterized microphysiological programs is more and more acknowledged to revolutionize therapeutic programmes. As we enter 2023, CN Bio is nicely positioned to construct upon its successes up to now and enter this thrilling subsequent stage of business progress and growth.”
Dr Paul Brooks, CEO, CN Bio
Dr David Hughes, beforehand CEO, CN Bio, commented: “Since becoming a member of the group, Paul has been a driving power for initiating the subsequent part of CN Bio’s improvement. His breadth of trade expertise, paired with in depth technical experience, is a large asset to the Firm as CEO, and I’m assured that he’ll efficiently proceed our mission to rework drug discovery. My honest thanks go to the group, who I’ve labored alongside for 12 years, and I now stay up for supporting CN Bio’s innovation and progress in an advisory position.”
